PMC7446375_01
Treatment schedule and ESR1 mutations. SHIVA02, Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (ClinicalTrials.gov identifier: NCT03084757).
PO.18.00398f1.jpg
PMC7446375_01_PO.18.00398f1.jpg
f1
The patient was then biopsied in the framework of the SHIVA02 trial (Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control; ClinicalTrials.gov identifier: NCT03084757), which aimed to identify druggable molecular alterations, and received a fourth line of chemotherapy with gemcitabine (Fig 1). No ESR1 amplification was identified (Fig 1). However, AKT1 (c.49G>A; p.E17K) and CTTNB1 (c.100G>A; p.G34R) mutations were observed in the primary tumor with 71% and 36% allelic ratios, respectively, which were comparable to mutations found in the distant metastasis (Fig 1).